So…
how did the Black civil rights groups
end up attached at the hip with LBGT rights ?
And
suppose your civil rights were not quite the same
as the right to practice degrading sex acts ?
or to promenade in the streets naked and drunk ?
or to endure a sexual come-on from a homosexual activist ?
What is wrong with this picture ?
One is based on a moral respect for others.
One is not.
Keystone
This will all be related to Dr. Anthony Fauci
who began AIDS research in 1984 and hasn't yet found a cure
but has been in charge of all funding at NIH for over 30 years.
Billions go to pharma corporations and some "start ups" too.
----–
https://www.iavireport.org/vol-13-no-2-mar-apr-2009/1030-capsules-from-keystone
CAPSULES FROM KEYSTONE
Mar-Apr 2009
A lot of snow fell the week of March 22-27 in Keystone, Colorado, accompanied by a flurry of updates on vaccine research and development by researchers who gathered for the joint Keystone Symposia on “HIV Immunobiology: From Infection to Immune Control” and “Prevention of HIV/AIDS.”
This year’s meeting marked the 25th anniversary of Keystone Symposia’s first meeting on HIV/AIDS, which was held in 1984, three years after the first HIV infections were described. The speakers at the conference’s opening session left no doubt that 28 years after HIV emerged, there is still much to do. “We probably got rid of the iceberg, but under the water there is a mass of ice and that’s the current AIDS epidemic,” said Didier Trono, of the Ecole Polytechnique Federale de Lausanne, in his introductory address. Nobel laureate Francoise Barre-Sinoussi from the Institut Pasteur said recent developments in the AIDS vaccine field show that “we have to come back to basic science.”
other subject headings:
Tracking transmission
DNA/Ad5 against rigorous challenge
DNA prime doesn’t pay
Building a better antigen
STEP by step
Mucosal protection
Antibodies: Better together or alone?
HIV-specific T cells in the gut
Non-pathogenic SIV infection
Battlefield maps
HSV-2 Infection and HIV risk
Dr. Fauci research continued
-–
This report is backed with 20 indexed references, some of which include HCQ
https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.1780390122
ARTHRITIS & RHEUMATISM
Vol. 39, No. 1, January 1596, pp 157-161
6 1996, American College of Rheumatology
MATTHEW H. ORNSTEIN and KIRK SPERBER
THE ANTIINFLAMMATORY AND ANTIVIRAL EFFECTS OF
HYDROXYCHLOROQUINE IN TWO PATIENTS WITH
ACQUIRED IMMUNODEFICIENCY SYNDROME AND
ACTIVE INFLAMMATORY ARTHRITIS
(excerpts)
The antibiotic and antiviral properties of HCQ may also have been of help to our 2 patients. Neither patient developed an opportunistic infection while taking HCQ, although this may have simply been a matter of chance.
It is important to note that antimalarial medications also have antiprotozoal effects that could help to prevent opportunistic infections such as PCP and Toxoplusmu gondii (16,17). Indeed, the antimalarial drug primaquine is part of a current alternative regimen for treating active PCP in patients who cannot tolerate TMP/SMX (16). Patient 1 had been taking HCQ for 14 months, and developed PCP only after cessation of HCQ and TMP/SMX.
It has long been suspected that RA and other types of inflammatory arthritis may have a viral origin.
Using a medication that inhibits viral replication could theoretically decrease an inflammatory process by suppressing the cause.
The ability of HCQ to inhibit the replication of HIV (as well as other viruses) in vitro and in vivo suggests that it may be a good candidate treatment for patients with
an AIDS-associated arthritis.
All of the other options have considerable toxic side effects when compared with HCQ, and none possess its unique antiviral properties.
If HCQ can treat inflammatory arthritis associated with AIDS as well as act to inhibit HIV replication, it may be a drug of choice in these patients.
We are not suggesting that all patients with AIDS and various inflammatory arthropathies will improve with antimalarial therapy, only that there are multiple reasons for choosing HCQ over other agents.
Extreme caution would, of course, be needed in treating patients who have psoriatic arthritis with HCQ, so that the skin rash would not be exacerbated.
From the preliminary data presented, we believe that HCQ should now be studied in a controlled trial for patients with inflammatory arthritis who are HIV positive, in order to assess the benefits in both diseases.
—
That was in 1996
Dr. Fauci continued
----–
no studies had been done on HCQ ?
-–
https://health.ucsd.edu/news/releases/Pages/2020-05-15-nih-begins-clinical-trial-of-hydroxychloroquine-azithromycin-to-treat-covid-19.aspx
https://archive.is/wip/kXiig
NIH Begins Clinical Trial of Hydroxychloroquine and Azithromycin to Treat
COVID-19
A Q&A with the trial’s study team leader, Davey Smith, MD, at UC San Diego
School of Medicine
May 15, 2020 | Scott LaFee
(my note: claims made in this report do not have reference source links)
--
…But other studies have found no improvement and, in fact, report that patients receiving both drugs together were more likely to experience cardiac arrest than those who received one or neither of the therapies.
As a result, the FDA cautions that hydroxychloroquine for COVID-19 be limited to clinical trials or for treating certain hospitalized patients under emergency use authorization so clinicians can closely monitor patients for adverse effects.
Question: How is this trial different from earlier studies or investigations?
Smith: Other trials were not conducted in a way that allowed for observers and reviewers to conclude with certainty that the approach works or does not. Questions or aspects were left unanswered or incomplete.
Question: How do the drugs work?
Smith: By increasing the pH of certain cellular components called endosomes, which the novel coronavirus uses to infect cells. Endosomes are compartments inside a cell’s membrane that serve as a place where materials pulled into the cell can be sorted and directed to destinations inside the cell and materials inside can be transported and moved outside the cell. If the pH is too high in these endosomes, the virus gets stuck and cannot finish infecting the cell.
Question: How long do you expect the trial to run? Do you expect difficulty finding participants, given concerns and controversy regarding this approach? When might initial results be known?
Smith: We expect the study to run a few months. I do not know if we will have difficulty finding eligible participants. There is still a lot of COVID-19 in the community and we do not currently have a medication that works for people who are not hospitalized.
Dr Fauci continued
----–
https://pubmed.ncbi.nlm.nih.gov/22820788/
https://archive.is/wip/x6r2o
JAMA. 2012 Jul 25;
308(4):353-61. doi: 10.1001/jama.2012.6936.
Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-infected Patients Not Receiving Antiretroviral Therapy: A Randomized Controlled Trial
Intervention: Hydroxychloroquine, 400 mg, or matching placebo once daily for 48 weeks.
Among HIV-infected patients not taking antiretroviral therapy, the use of hydroxychloroquine compared with placebo did not reduce CD8 cell activation but did result in a greater decline in CD4 cell count and increased viral replication.
linked to from: http://www.isrctn.com/ISRCTN30019040
==
https://www.sciencedirect.com/science/article/abs/pii/0149291895800395
https://archive.is/wip/o7dvv
Clinical Therapeutics
Volume 17, Issue 4, July–August 1995, Pages 622-636
Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1
Hydroxychloroquine (HCQ), an antimalarial agent used to treat patients with autoimmune diseases, has been shown to suppress human immunodeficiency virus type 1 (HIV-1) replication in vitro in T cells and monocytes
HCQ thus may be useful in the treatment of patients with HIV-1 infection.
===
https://www.aidsmap.com/news/jul-2016/hiv-will-only-be-cured-combinations-too-conference-delegates-hear
https://archive.is/dIDw5
Dr Anthony Fauci, head of the US National Institute of Allergies and Infectious Diseases, told delegates that HIV cure research was roughly at the stage HIV treatment was in 1990; as with the first HIV drug AZT (zidovudine), it was becoming clear that single agents or strategies might only have the most limited effect, and dual combinations were starting to show somewhat more promise.
Even combinations don’t work if they lack a crucial step in the sequence of events that would need to happen for HIV-infected cells to be purged from the body. The Towards a Cure workshop, and the main conference, heard about disappointing results from an experimental regimen consisting of three drugs; the immune modulator drug vorinostat, chosen because it can ‘wake up’ the long-lived reservoir cells in which HIV lies hidden; the anti-malaria drug hydroxychloroquine, chosen to contain the immune stimulant effects of vorinostat and prevent runaway HIV infection; and the entry inhibitor maraviroc, chosen because it has the potential to stop HIV spreading to new cells once the reservoir cells are woken up.
This ‘VHM’ combination was given to ten people with HIV who had been diagnosed within two to four weeks of infection, treated immediately with antiretroviral therapy (ART) and kept on ART for at least two years. It was hoped that the ‘kick’ given by this regimen would induce the body’s immune system to spontaneously eliminate the HIV-infected cells that had now become visible to it, or would convert naturally to a short-lived type that would die.
Presenter Jintanat Ananworanich told the workshop that the reason VHM did not work was probably because, as other ‘kick and kill’ studies had found, that it was not enough to flush the HIV reservoir cells out of hiding. It turned out that the body’s natural immune processes did not then kill these calls and that a ‘kill’ component or toxin that actively targeted the reawakened reservoir cells would have to be added.
https://www.hiv.gov/blog/dr-fauci-discusses-ending-hiv-epidemic-2019-ias-conference-hiv-science
https://archive.is/wip/PSQSH
Dr. Fauci Discusses Ending the HIV Epidemic from the 2019 IAS Conference on HIV Science
HIV.gov | Published: July 23, 2019
Dr. Fauci explained that research continues for a safe and effective HIV vaccine because that will be a “nail in the coffin” for the epidemic. Since it can be challenging to get the existing HIV prevention and treatment tools to all those who need them, he noted, “if you want a truly global, effective, durable end to the epidemic, the only way you’re going to do that is with a safe and effective vaccine together with all the other preventative modalities.”
Asked if he is optimistic about whether we can truly end the epidemic with the available tools and new science, Dr. Fauci affirmed that he is. “I don’t think it will be easy and I don’t think it will happen spontaneously. A lot of effort has to be put into it. But the one thing I’m absolutely certain of is that it’s possible…Right now it’s definitely possible. We just need to do it.”
https://www.iavireport.org/vol-13-no-2-mar-apr-2009/1031-a-living-history-of-aids-vaccine-research-part1-anthony-fauci
Anthony Fauci has been at the forefront of AIDS vaccine research for decades. When AIDS surfaced in 1981, he, like many other scientists and physicians, was drawn to the mysterious illness, which has now claimed more than 25 million lives—more than the populations of Ghana or Taiwan. Since 1984, he has served as director of the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health (NIH). He has been a key advisor to US presidents on global AIDS issues and was a leading architect of the US President’s Emergency Plan for AIDS Relief (PEPFAR). Born on Christmas Eve, 1940, and raised above a pharmacy in Brooklyn, New York, he earned a medical degree from Cornell Medical College. Fauci, a marathoner, avid fisherman, and father of three, has invited AIDS activists into his home. Last year, he presided over a US$4.4 billion budget—roughly a third of it dedicated to HIV/AIDS research.
"I don’t see myself as a politician, I see myself as an honest broker of science. That’s
the reason I think I’ve been able to be effective," Fauci said